Plixorafenib is under clinical development by Fore Biotherapeutics and currently in Phase II for Glioma. According to GlobalData, Phase II drugs for Glioma have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Plixorafenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plixorafenib overview

FORE-8394 (PLX-8394) is under development for the treatment of solid tumors, high grade glioma, low grade glioma, anaplastic astrocytoma, high grade astrocytoma with piloid features, gliosarcoma, anaplastic pleomorphic xanthoastrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma and glioblastoma multiforme. The drug candidate is a next-generation small molecule administered orally. The drug candidate targets BRAF.

It was under development for hairy cell leukemia, advanced malignancies, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, ganglioglioma, astrocytoma, papillary craniopharyngioma, glioblastoma and other leukemias. 

Fore Biotherapeutics overview

Fore Biotherapeutics, formerly known as NovellusDx, is a precision oncology company that focuses on the development of its lead program FORE8394 (formerly PLX-8394) platform, a next generation treatment for class I or II BRAF mutations and fusions, V600 and non-V600 BRAF mutations. FORE8394 is a small molecule that only targets cancer cells with a mutated BRAF gene. The company employs functional genomics to develop treatments that improve the lives of patients suffering from rare cancers. It develops treatments for patients with cancers that are genetically defined. Fore Biotherapeutics is headquartered at Philadelphia, Pennsylvania, the US.

For a complete picture of Plixorafenib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.